Today: 30 April 2026
Browse Category

NASDAQ:OTLK 13 November 2025 - 1 January 2026

Outlook Therapeutics stock drops after FDA issues another Lytenava CRL for wet AMD

Outlook Therapeutics stock drops after FDA issues another Lytenava CRL for wet AMD

Outlook Therapeutics shares dropped from $1.58 to about $0.58 after hours on Dec. 31 after the FDA issued a third complete response letter declining approval for its Lytenava wet-AMD drug. The FDA said more confirmatory efficacy evidence is needed but did not specify requirements. The drug is already approved in the EU and UK. U.S. markets reopen Friday after the New Year’s holiday.
1 January 2026
··
Outlook Therapeutics stock jumps ahead of FDA’s Dec. 31 Lytenava decision

Outlook Therapeutics stock jumps ahead of FDA’s Dec. 31 Lytenava decision

Outlook Therapeutics shares closed Monday up 8.8% at $1.98, then rose about 2% in after-hours trading ahead of the FDA’s Dec. 31 decision deadline for Lytenava in wet AMD. The stock remains volatile after an August FDA rejection sent shares down nearly 70%. Trading volume has surged, with the 20-day average at 3.35 million shares. Investors are watching for the FDA’s move, which could come outside regular market hours.
30 December 2025
·
Outlook Therapeutics (OTLK) Soars as FDA Accepts ONS‑5010 BLA and Sets December 31, 2025 Review Date

Outlook Therapeutics (OTLK) Soars as FDA Accepts ONS‑5010 BLA and Sets December 31, 2025 Review Date

Outlook Therapeutics shares rose about 22% after the FDA accepted its resubmitted Biologics License Application for ONS‑5010/LYTENAVA as a treatment for wet AMD, setting a PDUFA review date of December 31, 2025. The FDA classified the filing as a complete, Class 1 response, triggering a 60-day review. The move follows an August rejection over insufficient efficacy data. ONS‑5010/LYTENAVA is already approved in the EU and UK.
13 November 2025
··

Stock Market Today

  • ASX set to slide as oil prices jump over $120 a barrel
    April 29, 2026, 6:07 PM EDT. The Australian share market (ASX) is expected to open lower, with futures down 0.8% to 8,627 points, following mixed results on Wall Street. The Dow Jones fell 0.6%, S&P 500 slipped 0.04%, while the Nasdaq rose 0.6%. European markets also declined, led by the FTSE down 1.2%. Oil prices surged 8.7% to over $US120 a barrel, driven by Brent crude hitting $US120.92. Commodities like iron ore rose 0.6%, while precious metals and the Australian dollar weakened. This sharp oil price increase pressures markets and is a key factor behind the ASX's anticipated drop. The market will be closely watching further economic and commodity developments throughout the trading day.

Latest article

Microsoft Stock Falls After Earnings Beat as Azure Growth Hits 40% and AI Revenue Surges

Microsoft Stock Falls After Earnings Beat as Azure Growth Hits 40% and AI Revenue Surges

29 April 2026
Microsoft reported fiscal Q3 revenue of $82.9 billion, up 18%, and net income of $31.8 billion, up 23%, beating analyst estimates. Azure revenue jumped 40%, and AI business annual run rate hit $37 billion, up 123%. Shares fell over 2% after hours as investors focused on rising capital expenditures, which climbed 49% to $31.9 billion. Free cash flow dropped to $15.8 billion from $20.3 billion a year earlier.
Meta Stock Slides as $145 Billion AI Spending Plan Overshadows Blowout Earnings

Meta Stock Slides as $145 Billion AI Spending Plan Overshadows Blowout Earnings

29 April 2026
Meta Platforms shares dropped about 5% in after-hours trading Wednesday after the company raised its 2026 capital spending forecast to $125–$145 billion. First-quarter revenue rose 33% to $56.31 billion, beating estimates, while net income reached $26.77 billion, boosted by an $8.03 billion tax benefit. Meta expects second-quarter revenue of $58–$61 billion. Daily active users across its apps increased 4% to 3.56 billion.
Chipotle Stock Jumps After Chicken Bet Breaks Its Sales Slump

Chipotle Stock Jumps After Chicken Bet Breaks Its Sales Slump

29 April 2026
Chipotle Mexican Grill reported a 0.5% rise in first-quarter comparable sales, reversing recent declines and beating analyst expectations. Total revenue rose 7.4% to $3.09 billion, while shares jumped 7% in after-hours trading. Operating margin narrowed to 12.9% from 16.7% a year earlier. Menu items like Chicken al Pastor and Honey Chicken drove increased restaurant visits.
Go toTop